NK cell therapy with T-Dxd for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment that combines a type of immune cell called NK cells with a targeted drug called T-Dxd for people with advanced breast cancer that has stopped responding to other treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that has spread or cannot be removed with surgery, and standard treatments are no longer working.
- You must be at least 18 years old.
- If you have triple-negative breast cancer, you must have already tried a drug called sacituzumab govitecan or a similar antibody-drug conjugate.
- You must have at least one tumor that can be measured on a scan or exam.
- You must be able to care for yourself (performance status 0 or 1).
- You must have adequate organ function, including kidneys, liver, heart, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This study tests a new treatment using natural killer (NK) cells that are specially created in the lab to find and attack cancer cells that have a protein called CD5 on their surface. The treatment is given along with chemotherapy to help the NK cells work better. It may be an option for people with certain types of T-cell lymphoma or leukemia that have not responded to other treatments.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.